Literature DB >> 18343784

CDX2 and villin are useful markers of intestinal metaplasia in the diagnosis of Barrett esophagus.

Xue Ying Shi1, Brahm Bhagwandeen, Anthony S-Y Leong.   

Abstract

The identification of intestinal metaplasia (IM) in the esophagus is necessary for the selection of patients with Barrett esophagus (BE) for surveillance. We studied 108 esophageal biopsy and resection specimens, clinically diagnosed as BE, and stained them for CDX2, villin, HepPar-1, and cytokeratin (CK) 7 to investigate sensitivity for identifying IM. H&E-stained sections showed definite goblet cells in 94 cases. CDX2 and villin were positive in all 94 cases. Of 38 cardia- and 9 fundic-type mucosa samples associated with BE, 13 (34%) and 0 (0%) displayed CDX2 positivity and 21 (55%) and 1 (11%) displayed villin positivity, respectively. HepPar-1 was positive in 54 (57%) of 94 cases with IM and negative in the associated cardia- and fundic-type mucosa. A full-thickness CK7 staining pattern was present in 90 (96%) of samples with IM and 22 (58%) and 0 (0%) of the associated cardia- and fundic-type mucosa, respectively. None of 20 control samples of morphologically normal gastric mucosa stained for CDX2 or villin. CDX2 and villin are sensitive markers for early-stage IM and can supplement the histologic identification of this premalignant condition in the esophagus.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18343784     DOI: 10.1309/UWK3NAHV31GFHM3J

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  6 in total

1.  CDX-2 Expression in Esophageal Biopsies Without Goblet Cell Intestinal Metaplasia May Be Predictive of Barrett's Esophagus.

Authors:  James Saller; Sameer Al Diffalha; Kevin Neill; Rahill A Bhaskar; Cecilia Oliveri; David Boulware; Henry Levine; Isaac Kalvaria; F Scott Corbett; Arun Khazanchi; Jason Klapman; Domenico Coppola
Journal:  Dig Dis Sci       Date:  2019-11-05       Impact factor: 3.199

2.  Hepatocyte paraffin 1 antigen as a biomarker for early diagnosis of Barrett esophagus.

Authors:  Jennifer A Jeung; Justin J Coran; Chen Liu; Diana M Cardona
Journal:  Am J Clin Pathol       Date:  2012-01       Impact factor: 2.493

3.  Inhibition of nucleostemin upregulates CDX2 expression in HT29 cells in response to bile acid exposure: implications in the pathogenesis of Barrett's esophagus.

Authors:  Yong-Gang Sun; Xing-Wei Wang; Shi-Ming Yang; Gang Zhou; Wei-Qiang Wang; Hong-Bin Wang; Rong-Quan Wang; Dian-Chun Fang
Journal:  J Gastrointest Surg       Date:  2009-05-16       Impact factor: 3.452

4.  Altered expression of CD44 and DKK1 in the progression of Barrett's esophagus to esophageal adenocarcinoma.

Authors:  T Darlavoix; W Seelentag; P Yan; A Bachmann; F T Bosman
Journal:  Virchows Arch       Date:  2009-04-25       Impact factor: 4.064

5.  HDAC6/HNF4α loop mediated by miR-1 promotes bile acids-induced gastric intestinal metaplasia.

Authors:  Na Wang; Min Chen; Zhen Ni; Ting Li; Jiaoxia Zeng; Guofang Lu; Jiaojiao Wang; Jian Zhang; Siran Wu; Yongquan Shi
Journal:  Gastric Cancer       Date:  2020-07-23       Impact factor: 7.370

6.  Expression profiling of CPS1 in Correa's cascade and its association with gastric cancer prognosis.

Authors:  Xuqian Fang; Xiaoqiong Wu; Enfei Xiang; Fangxiu Luo; Qinqin Li; Qianchen Ma; Fei Yuan; Peizhan Chen
Journal:  Oncol Lett       Date:  2021-04-02       Impact factor: 2.967

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.